Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel

M. Paithankar, M. Bhalekar
{"title":"Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel","authors":"M. Paithankar, M. Bhalekar","doi":"10.25004/ijpsdr.2022.140115","DOIUrl":null,"url":null,"abstract":"Cabazitaxel (CTX), a novel taxane derivative, has proven effective in many solid tumors. It is also approved in many countries for multiple uses in solid tumors. The current marketed formulation lacks the tumortargeting ability, and its uneven distribution in the body causes toxicity to normal tissues. Further, it is a surfactant (polysorbate 80) based micellar formulation composed of ethanol as a co-solvent to improve the solubility of CTX, which causes severe and life-threatening side effects. Hence, to avoid the problem\nassociated with this conventional CTX formulation, the nanoparticulate drug delivery system of CTX was\ndeveloped by employing the Quality by Design (QbD) approach. The CTX nanoparticulate system was\ndeveloped by employing a bottom-up followed by a top-down approach. The size reduction was obtained\nby High-Pressure Homogenizer (HPH). The formulation optimization was done using QbD approach. Design\nof experiments (DoE) was used to understand the effect of various formulation and process variables on\na dependent variable like particle size distribution.\nThe stabilizer concentration, concentration of solubilizer, HPH pressure, and passes were selected as\nindependent factors while particle size distribution was selected as a dependent factor for evaluation.\nThe nanoparticulate system was developed using PEG-400 as solubilizing agents, while Soya\nPhosphatidylcholine (SPC) was used as a surface stabilizer. Response surface plots revealed a decrease in\nparticle size with increasing concentration of SPC and PEG 400. Similarly, a decrease in particle size with increased HPH passes and pressure was found. The optimum concentrations of SPC and PEG 400 were\nfound to be 20% and 2.5%, respectively. 20 KPSI pressure and 5 HPH passes were derived as optimized\nprocessing parameters from DoE. The optimized formulation had a size of 43.5 nm, with PDI is less than 0.4. Due to its narrow particle size distribution, the formulation did not show any increase in particle size or aggregation up to 24 hours. The present research confirms the feasibility of developing the nanoparticulate system of CTX using the bottom-up followed by the top-down technique. The formulation was systematically optimized using QbD approach. The optimum concentration of PEG 400 as solubilizer and concentration of SPC as stabilizer was obtained from DoE, yielding optimum particle size and stability","PeriodicalId":14278,"journal":{"name":"International Journal of Pharmaceutical Sciences and Drug Research","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Sciences and Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25004/ijpsdr.2022.140115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Cabazitaxel (CTX), a novel taxane derivative, has proven effective in many solid tumors. It is also approved in many countries for multiple uses in solid tumors. The current marketed formulation lacks the tumortargeting ability, and its uneven distribution in the body causes toxicity to normal tissues. Further, it is a surfactant (polysorbate 80) based micellar formulation composed of ethanol as a co-solvent to improve the solubility of CTX, which causes severe and life-threatening side effects. Hence, to avoid the problem associated with this conventional CTX formulation, the nanoparticulate drug delivery system of CTX was developed by employing the Quality by Design (QbD) approach. The CTX nanoparticulate system was developed by employing a bottom-up followed by a top-down approach. The size reduction was obtained by High-Pressure Homogenizer (HPH). The formulation optimization was done using QbD approach. Design of experiments (DoE) was used to understand the effect of various formulation and process variables on a dependent variable like particle size distribution. The stabilizer concentration, concentration of solubilizer, HPH pressure, and passes were selected as independent factors while particle size distribution was selected as a dependent factor for evaluation. The nanoparticulate system was developed using PEG-400 as solubilizing agents, while Soya Phosphatidylcholine (SPC) was used as a surface stabilizer. Response surface plots revealed a decrease in particle size with increasing concentration of SPC and PEG 400. Similarly, a decrease in particle size with increased HPH passes and pressure was found. The optimum concentrations of SPC and PEG 400 were found to be 20% and 2.5%, respectively. 20 KPSI pressure and 5 HPH passes were derived as optimized processing parameters from DoE. The optimized formulation had a size of 43.5 nm, with PDI is less than 0.4. Due to its narrow particle size distribution, the formulation did not show any increase in particle size or aggregation up to 24 hours. The present research confirms the feasibility of developing the nanoparticulate system of CTX using the bottom-up followed by the top-down technique. The formulation was systematically optimized using QbD approach. The optimum concentration of PEG 400 as solubilizer and concentration of SPC as stabilizer was obtained from DoE, yielding optimum particle size and stability
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
以设计为导向的卡巴他赛纳米颗粒体系的开发与优化
卡巴他赛(Cabazitaxel, CTX)是一种新型的紫杉烷衍生物,已被证明对许多实体瘤有效。它也在许多国家被批准用于实体肿瘤的多种用途。目前上市的制剂缺乏肿瘤靶向能力,其在体内的不均匀分布会对正常组织产生毒性。此外,它是一种基于表面活性剂(聚山梨酯80)的胶束配方,由乙醇作为助溶剂组成,以提高CTX的溶解度,从而导致严重和危及生命的副作用。因此,为了避免与传统CTX制剂相关的问题,采用设计质量(QbD)方法开发了CTX的纳米颗粒给药系统。CTX纳米颗粒系统是采用自下而上的方法开发的,然后是自上而下的方法。采用高压均质机(HPH)实现了颗粒的减小。采用QbD法对其配方进行优化。采用实验设计法(DoE)了解不同配方和工艺变量对粒径分布等因变量的影响。以稳定剂浓度、增溶剂浓度、高压ph压力和通道为独立因素,以粒径分布为依赖因素进行评价。以PEG-400为增溶剂,大豆磷脂酰胆碱(SPC)为表面稳定剂,制备了纳米颗粒体系。响应面图显示,随着SPC和peg400浓度的增加,颗粒尺寸减小。同样,随着HPH孔道数和压力的增加,颗粒尺寸也会减小。SPC和peg400的最佳浓度分别为20%和2.5%。从DoE中得到了20个KPSI压力和5个HPH通道作为优化的工艺参数。优化后的配方尺寸为43.5 nm, PDI小于0.4。由于其粒度分布窄,该配方在24小时内没有显示出粒度或聚集的任何增加。本研究证实了采用自下而上再自上而下的技术开发CTX纳米颗粒系统的可行性。采用QbD法对配方进行了系统优化。通过实验确定了最佳的增溶剂PEG 400和稳定剂SPC的浓度,得到了最佳的粒径和稳定性
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Isolation, Characterization, In-silico and Enzyme Inhibition Studies of Bougainvillea spectabilis against a Hyperoxaluria Initiator Glycolate Oxidase Development and Optimization of Enzalutamide Nanosuspension by Design of Experiments for Dissolution Enhancement Expeditious Microwave-assisted Synthesis of 1,3-Benzoxazoles Incorporating Substituted Thiazolidinone Moieties Detection of 3-4 Methylenedioxyamphetamine from Drug Abuser’s Fingers and Toenails using Liquid Chromatography with Mass Spectroscopy GC-MS Analysis and In-silico Docking Study of Active Antifungal Components of Entada rheedei Spreng. (Seeds)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1